| CAS NO: | 331963-29-2 |
| 包装 | 价格(元) |
| Free Sample (0.1-0.5mg) | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| Cas No. | 331963-29-2 |
| 别名 | 1-乙基-1,2-二氢-4-羟基-2-氧代-3-喹啉羧酸2-(1-氧代十三烷基)酰肼 |
| Canonical SMILES | O=C1C(C(NNC(CCCCCCCCCCCC)=O)=O)=C(O)C2=CC=CC=C2N1CC |
| 分子式 | C25H37N3O4 |
| 分子量 | 443.58 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | I2906 showed antimycobacterial and cytotoxic activity against mycobacterium tuberculosis.IC50 Value: Target: AntibacterialUnder in vitro conditions, I2906 showed excellent antimycobacterial activities and low cytotoxicity. In a murine model infected with M. tuberculosis H37Rv, the reductions on bacterial loads of both lungs and spleen were statistically significant (p< 0.05) between I2906-treated mice and untreated controls after 4 weeks. Further, the colony-forming unit counts in the lungs were dramatically lower (p< 0.05) than that of isoniazid-treated mice by the addition of I2906 after 8 weeks. Moreover, survival rate was increased by I2906 treatment. For multidrug-resistant strain infection, bacterial counts were reduced significantly in the lungs and spleen due to I2906 treatment in comparison with data from untreated controls (p< 0.05). [1]. Lu, Jingning; Yue, Jun; Wu, Jing et al. In vitro and in vivo Activities of a New Lead Compound I2906 against Mycobacterium tuberculosis. Pharmacology (2010), 85(6), 365-371. |
m.cnreagent.com